Metoclopramide Response in Patients With Progressive Systemic Sclerosis: Effect on Esophageal and Gastric Motility Abnormalities

Archives of Internal Medicine

Volumn 147, Issue 9, 1987, Pages 1597-1601

  Johnson, David A ^a,b   Drane, Walter E ^a   Curran, James ^a   Benjamin, Stanley B ^c   Chobanian, Sarkis J ^a,b   Karvelis, Kastytis ^a   Cattau, Edward L ^c  

^a Division of Gastroenterology Department of Medicine ^*  (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METOCLOPRAMIDE;

CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ESOPHAGUS; ESOPHAGUS TRANSIT TIME; HUMAN; INTESTINE MOTILITY; LOWER ESOPHAGUS SPHINCTER; MANOMETRY; MUSCLE; MUSCULOSKELETAL SYSTEM; PHARMACOKINETICS; SYNDROME CREST; SYSTEMIC SCLEROSIS; THERAPY;

ADULT; AGED; ESOPHAGUS; FEMALE; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; HUMAN; HYDROGEN-ION CONCENTRATION; MALE; MANOMETRY; METOCLOPRAMIDE; MIDDLE AGE; PRESSURE; SCLERODERMA, SYSTEMIC; SUPPORT, U.S. GOV'T, NON-P.H.S.;

EID: 0023191892     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1987.00370090075014     Document Type: Article

References (24)

1. 1. Poircer TJ, Rankin GB: Gastrointestinal manifestations of progressive systemic sclerosis based on a review of 364 cases. Am J Gastroenterol 1972;58:30-44.
2. 2. Cohen S, Laufer I, Snape WR Jr, et al: The gastrointestinal manifestations of scleroderma: Pathogenesis and management. Gastroenterology 1980;79:155-166.
3. 3. Clements PJ, Kadell B, Appoliti A, et al: Esophageal motility in progressive systemic sclerosis. Dig Dis Sci 1979;24:639-643.
4. 4. Creamer B, Anderson HA, Code CF: Esophageal motility in patients with scleroderma and related diseases. Gastroenterology 1976;86:763-775.
5. 5. Maddern GJ, Horowitz M, Jamieson GG, et al: Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology 1984;87:922-926.
6. 6. McCallum RW, Fink SM, Winnan GR, et al: Metoclopramide in gastroesophageal reflux disease: Rationale for its use and results of a double-blind trial. Am J Gastroenterol 1984;79:165-172.
7. 7. Fink SM, Lange RC, McCallum RW: Effect of metoclopramide on normal and delayed gastric emptying in gastroesophageal reflux patients. Dig Dis Sci 1983;28:1057-1061.
8. 8. Schulze-Delview K: Metoclopramide. Gastroenterology 1979;77: 768-779.
9. 9. Albibi R, McCallum RW: Metoclopramide: Pharmacology and clinical application. Ann Intern Med 1983;98:86-95.
10. 10. Johnson DA, Drane WE, Winters C Jr, et al: Solid-phase gastric emptying in Barrett’s esophagus. Dig Dis Sci 1986;31:1217-1220.
11. 11. Drane WE, Karvelis K, Johnson DA, et al: Progessive systemic sclerosis: Radionucleotide esophageal scintigraphy and manometry. Radiology 1986;160:73-76.
12. 12. Drane WE, Karvelis K, Johnson DA, et al: Scintigraphic detection of metoclopramide esophageal stimulation in progressive systemic sclerosis. J Nucl Med 1987;28:810-815.
13. 13. Ouyang A: Scleroderma and associated collagen vascular diseases, in Cohen S, Soloway RD (eds): Diseases of the Esophagus. New York, Churchill Livingstone Inc, 1982, pp 181-194.
14. 14. Barish CF, Wu WC, Castell DO: Respiratory complications of gastroesophageal reflux. Arch Intern Med 1985;145:1882-1888.
15. 15. Benjamin SB: Extra-esophageal complications of gastroesophageal reflux. J Clin Gastroenterol 1986;8(suppl 1):68-71.
16. 16. Denes P, Ducrotte P, Pasquis P, et al: Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 1981;42: 21-24.
17. 17. Cameron AJ, Payne WS: Barrett’s esophagus occurring as a complication of scleroderma. Mayo Clin Proc 1978;53:612-615.
18. 18. Ahtaridis G, Snape WJ, Cohen S: Clinical and manometric findings in benign peptic strictures of the esophagus. Dig Dis Sci 1979;24:858-861.
19. 19. Henderson RD, Pearson FG: Surgical management of esophageal scleroderma. J Thorac Cardiovasc Surg 1973;66:686-692.
20. 20. Ramirez-Mata M, Graciela I, Alarcon-Segovia D: Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients with PSS. Arthritis Rheum 1977;20:30-34.
21. 21. Dilawari JB, Misiewicz JJ: Action of metoclopramide on the esophageal junction in man. Gut 1973;14:380-382.
22. 22. Hertman P, Moller N: The effect of metoclopramide on the gastroesophageal junction zone and the distal esophagus in man. Scand J Gastroenterol 1970;5:620-626.
23. 23. Wallen L, Boesby S, Madsen T: Effect of metoclopramide on oesophageal peristalsis and gastro-oesophageal pressure. Scand J Gastroenterol 1979;14:923-927.
24. 24. McCallum RW: Review of the current states of prokinetic agents in gastroenterology. Am J Gastroenterol 1985;80:1008-1016.